Emend™ (fosaprepitant) – Expanded indication
April 3, 2018 - The FDA announced the approval of Merck’s Emend (fosaprepitant dimeglumine) for injection in pediatric patients 6 months of age and older in combination with other antiemetic agents for the prevention of Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
Top